Casa rexulti

Brexpiprazole for schizophrenia and as adjunct for major depressive disorder

Por um escritor misterioso

Last updated 06 julho 2024

Brexpiprazole for schizophrenia and as adjunct for major depressive disorder

מחקרים על ריקסלטי כטיפול אוגמנטציה בדיכאון (MDD)

Brexpiprazole - Mechanism of Action and Clinical Application

PDF] Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies

Frontiers Brexpiprazole in patients with schizophrenia with or without substance use disorder: an observational study

Rexulti (Brexpiprazole) for the Treatment of Major Depressive Disorder (MDD) and Schizophrenia - Clinical Trials Arena

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

PDF) Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator

Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials

REXULTI® (brexpiprazole), MDD

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study

Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: Role of BDNF-TrkB signaling

Life, Free Full-Text

Full article: Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study

Recomendado para você